New diabetes drug rongliflozin tested in patients with kidney problems

NCT ID NCT05374343

Completed Disease control Sponsor: Sunshine Lake Pharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested a single dose of the drug rongliflozin in 32 Chinese adults with type 2 diabetes who had normal, mildly, or moderately reduced kidney function. Researchers measured how the drug moved through the body and how it affected blood sugar and urine glucose. The goal was to see if kidney function changes how the drug works, which could guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rongliflozin (a drug taken by mouth)
What this could lead to: If successful, this could help doctors understand how rongliflozin works in people with type 2 diabetes and kidney problems, potentially leading to better blood sugar control.
What could go wrong: This is a very early (Phase 1) study with only 32 people, so results may not apply to everyone. The drug may not work as well in those with kidney impairment, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Ping Feng

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.